Jia Jenny Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on LinkedIn:
“ASCO Breakthrough is a different kind of oncology meeting; less about announcing a new drug and more about how innovation actually reaches patients.
It brings together clinicians, researchers, technologists, and health-system leaders to tackle the real bottleneck in modern cancer care: implementation.
Precision oncology now depends not only on discovery, but on deploying testing at scale, running trials across distributed populations, interpreting multi-omic data, and ensuring equitable access across regions. Progress in oncology will increasingly come from solving these delivery challenges, not just generating evidence.
The abstract submission deadline for ASCO Breakthrough in Singapore is Feb. 24 at 11:59 PM ET.
Join us this June to share your research with global oncology leaders. Submit now: breakthrough.asco.org.”
Other articles featuring Jia Jenny Liu on OncoDaily.